Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03529825 · ClinicalTrials.gov registry record · Early Phase 1
Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation
A Early Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 26
- Enrollment target
NCT03529825 is a Early Phase 1 study that has completed, run by Emory University. The registered enrollment target is 26 participants.
The verdict
NCT03529825, a Early Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
Primary purpose of the study is to see if rifaximin can improve the balance of bacteria within the gut, which has been shown to improve transplant outcomes. It will also assess whether rifaximin can reduce the risk of infection in blood/marrow transplant (BMT).
Interventions
- DRUG Rifaximin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-07-18 |
| Est. Completion | 2021-09-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03529825
The ClinicalTrials.gov registry entry for NCT03529825 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rifaximin is the first listed.
NCT03529825 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03529825 about?
NCT03529825 is a clinical study titled "Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation". Primary purpose of the study is to see if rifaximin can improve the balance of bacteria within the gut, which has been shown to improve transplant outcomes. It will also assess whether rifaximin can reduce the risk of infection in blood/marrow transplant (BMT).
What is the current status of trial NCT03529825?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 26 participants. The study started on 2018-07-18. Estimated completion is 2021-09-10.
What interventions are being tested in trial NCT03529825?
The interventions under investigation include: Rifaximin (DRUG).
Who is sponsoring clinical trial NCT03529825?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.